3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
37
Lymphoma, Follicular
22
Lymphoma, Mantle-Cell
18
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, B-Cell, Marginal Zone
11
Lymphoma, Non-Hodgkin
10
Lymphoma
6
Neoplasms
4
Lymphoma, B-Cell
4
Leukemia, B-Cell
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Neoplasm, Residual
2
Leukemia, Hairy Cell
2
Dendritic Cell Sarcoma, Interdigitating
2
Recurrence
1
Oncology Patients Receiving Chemotherapy
1
Neoplasm Metastasis
1
Lymphoproliferative Disorders
1
Indolent Non-Hodgkin's Lymphoma
1
Indolent Non-Hodgkin Lymphoma
1
Disease
1
Cytokine Release Syndrome
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Oncology Patients Receiving Chemotherapy
×
obinutuzumab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts